首页|Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
The interaction between cluster of differentiation 47(CD47)and signal regulatory protein α(SIRPα)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune homeostasis.Overexpression of CD47 occurs widely across various tumor cell types and transmits the"don't eat me"signal to macrophages to avoid phagocytosis through binding to SIRPα.Blockade of the CD47-SIRPα axis is therefore a promising approach for cancer treat-ment.Lymphoma is the most common hematological malignancy and is an area of unmet clin-ical need.This review mainly described the current strategies targeting the CD47-SIRPα axis,including antibodies,SIRPα Fc fusion proteins,small molecule inhibitors,and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.
Cancer treatmentCD47-SIRPα axisHodgkin lymphomaImmunotherapyNon-Hodgkin lymphoma
Pengcheng Zhao、Longyan Xie、Lei Yu、Ping Wang
展开 >
School of Life Sciences and Medicine,Shandong University of Technology,Zibo,Shandong 255000,China
Tongji University Cancer Center,Shanghai Tenth People's Hospital,School of Medicine,Tongji University,Shanghai 200092,China
国家重点研发计划国家自然科学基金国家自然科学基金国家自然科学基金Fundamental Research Funds for the Cornell University
NETL
NSTL
万方数据
